August 2025 in “Bioactive Materials” Ac-GFFY-IGF peptide is a promising, safe, and effective treatment for hair loss, better than current options.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
December 2024 in “Kufa Medical journal” Higher levels of IL-17A and IL-2 are linked to alopecia areata.
2 citations
,
November 2024 in “JAAD Case Reports” Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.
1 citations
,
January 2024 in “NPJ breast cancer” Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
97 citations
,
December 2011 in “New England Journal of Medicine” The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.
May 2026 in “Journal of Human Immunity” Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
November 2023 in “JEADV Clinical Practice” Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
October 2025 in “Science Advances” IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
January 2026 in “ACS Applied Bio Materials” A new treatment using nanoliposomes can improve hair regrowth in androgenetic alopecia.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
June 2025 in “Preprints.org” Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
245 citations
,
January 2010 in “Blood” Antihepcidin antibodies may treat inflammation-induced anemia by improving iron metabolism.
10 citations
,
December 2005 in “Aktuelle Dermatologie” Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.